Three vaccines report strong results in a month of hope
A month of strong vaccine trial results lifts hopes, while Delhi marks Diwali in what its leaders call a third wave.

NEW YORK, Monday 30 November.—Moderna said today it would ask US regulators for emergency authorisation of its coronavirus vaccine, capping a month in which three vaccine makers reported strong results from their trials.
The first came on 9 November, when Pfizer and its partner BioNTech said an interim analysis of 94 cases showed their vaccine was more than 90 per cent effective. “Today is a great day for science and humanity,” said Albert Bourla, Pfizer’s chairman and chief executive. On 18 November Pfizer reported final results showing 95 per cent efficacy and said it would seek US emergency authorisation within days.
Moderna followed on 16 November with 94.5 per cent in an interim analysis of 95 cases, only five of them in people given the vaccine. All 11 severe cases were in the placebo group. “We are going to have a vaccine that can stop COVID-19,” said Moderna’s president, Stephen Hoge.
Today is a great day for science and humanityAlbert Bourla
On 23 November AstraZeneca said the vaccine developed at Oxford averaged 70 per cent, rising to 90 per cent when a half dose was followed by a full dose, in an analysis of 131 infections in trials in Britain and Brazil. Prime Minister Boris Johnson called it “incredibly exciting news”.
Moderna said it would also apply to the European Medicines Agency. Regulators in Europe, Canada, Switzerland, Britain and Israel had already begun reviewing its data.
For this year, Pfizer and BioNTech expect to supply up to 50 million doses worldwide, and Moderna about 20 million ready to ship in the US.
Pfizer and BioNTech (press release, reproduced by Cambridge Network), Nov. 9 · Reuters (via Daily Maverick), Nov. 16 · Moderna (press release, reproduced by BioSpace), Nov. 16 · Reuters (via The Star, Kenya), Nov. 18 · ARY News, reproducing Reuters, Nov. 23 · Moderna (press release, reproduced by BioSpace), Nov. 30
